Antitumor Effect of CPT-11, a Camptothecin Derivative, on Human Testicular Tumor Xenografts in Nude Mice

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

“…The dose-limiting toxicities are severe diarrhoea and neutropenia. In vitro data demonstrated a dose-dependent activity of irinotecan against human testicular tumour xenografts (Miki et al, 1997). This provided the rationale for the present study which evaluates irinotecan in pretreated patients with refractory germ cell cancer.…”

“…The present phase II study investigates the activity of irinotecan in patients with intensively pretreated or cisplatin-refractory germ cell cancer. The rationale for the evaluation of irinotecan in testis cancer was based on the dose-dependent antitumour effect of irinotecan observed in human testicular tumour xenografts in nude mice either applied as single agent or in combination with cisplatin (Miki et al, 1997). A subsequent phase II study by Nomoto et al (2000) reported a very high response rate of 57% for the combination of irinotecan and cisplatin or nedaplatin in 14 cisplatinrefractory germ cell cancer patients suggesting that irinotecan may also be clinically active in refractory patients.…”

Current status and future perspectives in the treatment of advanced testicular cancer

“…[56][57][58][59][60][61][62][63][64][65][66][67][68][69] Paclitaxel was shown to Chemo., chemotherapy; CR, complete response; NED, no evidence of disease; VeIP, vinblastine, ifosfamide, cisplatin; VIP, etoposide (VP-16), ifosfamide, cisplatin. be effective for previously treated testicular cancer because of its unique mechanism of antitumor activity and the premature stabilization of the microtubules assembly, which is different from that of DNAdamaging agents such as cisplatin and ifosfamide.…”

“…The first trial of paclitaxel in pretreated germ cell tumors was undertaken by Motzer et al 56 The effective rate of paclitaxel in the salvage treatment of refractory testicular cancer ranged from 11 to 26% (Table 5). [56][57][58][59][60][61][62][63][64][65][66][67][68][69] More recently, high effective rates (68% and 80%) of a combination chemotherapy with paclitaxel, ifosfamide and cisplatin (TIP) in the treatment of refractory disease were reported by Beyer et al and Motzer et al 60,61 The results reported by Motzer et al showed a high response rate to the TIP regimen in patients with relapsed testicular cancer after conventional dose first-line chemotherapy. 61 Motzer and associates also reported the result of dose-intensive salvage therapy with paclitaxel, ifosfamide, carboplatin and etoposide (PICP) for cisplatin-resistant germ cell tumor patients with unfavorable prognostic features, achieving a 57% CR rate.…”

“…67,68 In recent years, we reported the results of salvage chemotherapy with a combination of irinotecan hydrochloride and cisplatin or nedaplatin for refractory testicular cancer. 69 Six of the 14 patients (42.9%) treated with irinotecan-based combination chemotherapy achieved NED with/without following surgery.…”